Cuorips Inc. (4894.T)
JPY 7080.0
(13.28%)
JPY 7080.0
(13.28%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 23.1 Million JPY | -39.65% |
| 2022 | 38.27 Million JPY | 175.12% |
| 2021 | 13.91 Million JPY | 6224.09% |
| 2020 | 220 Thousand JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 186 Thousand JPY | -97.68% |
| 2023 FY | 23.1 Million JPY | -39.65% |
| 2023 Q4 | 8 Million JPY | 140.65% |
| 2023 Q3 | 3.32 Million JPY | -57.75% |
| 2023 Q1 | 3.9 Million JPY | -84.27% |
| 2023 Q2 | 7.87 Million JPY | 101.85% |
| 2022 FY | 38.27 Million JPY | 175.12% |
| 2022 Q4 | 24.79 Million JPY | 0.0% |
| 2021 FY | 13.91 Million JPY | 6224.09% |
| 2020 FY | 220 Thousand JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 99.516% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | 79.542% |
| GNI Group Ltd. | 26.01 Billion JPY | 99.911% |
| Linical Co., Ltd. | 12.3 Billion JPY | 99.812% |
| Trans Genic Inc. | 13.08 Billion JPY | 99.823% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 96.508% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 99.552% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 98.519% |
| AnGes, Inc. | 152.98 Million JPY | 84.899% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | 96.214% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 99.819% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 97.171% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | 82.952% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 98.579% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 94.607% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 98.785% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 96.615% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 99.05% |
| PeptiDream Inc. | 28.71 Billion JPY | 99.92% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | 63.352% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | 80.907% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -31986.111% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | 42.081% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 99.488% |
| FunPep Company Limited | 530 Thousand JPY | -4258.868% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 66.64% |
| Stella Pharma Corporation | 269.49 Million JPY | 91.428% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | 92.708% |
| K Pharma,Inc. | 1 Billion JPY | 97.69% |
| Takara Bio Inc. | 43.5 Billion JPY | 99.947% |
| ReproCELL Incorporated | 2.42 Billion JPY | 99.048% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 98.653% |
| StemCell Institute Inc. | 2.48 Billion JPY | 99.069% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 99.081% |
| CellSeed Inc. | 190.13 Million JPY | 87.85% |